The Abbott settlement announced on September 14 requires the company to pay nearly $385 million, plus interest, to resolve a dispute over infant formula purchased with public money. Federal officials alleged that products supplied to government programs failed to meet manufacturing requirements between 2018 and 2022. Justice Department announcement.

Abbott denies the allegations, and the agreement contains no admission of facts or liability. The company described the resolution as covering the federal investigation and lawsuit, along with claims brought by whistleblowers and state attorneys general. Both sides have agreed to settle a contested case rather than carry it through a trial. Abbott’s response.

Where the Abbott settlement money goes

The agreement separates the payments into three parts: about $348.7 million for the federal government, $35.5 million for participating state Medicaid programs, and $806,884 for Massachusetts’ supplemental WIC funding. The combined principal is $384,999,040.12. Interest is additional, so the rounded headline figure is not the final amount due. Settlement agreement, paragraph 1.

The public programs explain why a manufacturing dispute became a government-payment case. WIC, the Special Supplemental Nutrition Program for Women, Infants, and Children, helps eligible participants obtain nutrition, including formula. Medicaid also pays for certain formula products. DOJ says more than half of U.S. infant formula purchases are funded through WIC, making compliance by suppliers a significant public spending issue. DOJ’s explanation of the programs.

Three Abbott employees brought the whistleblower action: Scott Millard, Kristine Cooper and Loren Cooper. DOJ says they will receive $69 million from the federal recovery. The False Claims Act allows private people to sue on the government’s behalf and share in recoveries. Their award is part of the federal portion of the Abbott settlement, rather than another $69 million added to the company’s principal payment. DOJ’s account of the whistleblower case.

Manufacturing allegations and Abbott’s response

The allegations behind the Abbott settlement focus on manufacturing conditions and whether the government paid for compliant products. Reporting by Lisa Schencker describes the government’s claims about leaking roofs and cracks in equipment used to turn liquid formula into powder. The alleged problem was the risk created by those conditions; the settlement itself does not decide that any particular infant became ill because of Abbott formula. Schencker’s report in the Daily Herald.

In responding to the Abbott settlement, the company emphasized testing of its products. Abbott said no unopened, distributed formula had tested positive for Cronobacter sakazakii and said regulators’ tests of unopened containers from the affected households were negative. It also pointed to the absence of a definitive link between the Sturgis plant and the investigated illnesses. Those are the company’s stated reasons for disputing responsibility, alongside its acceptance of the financial agreement. Company statement and testing account.

How the case connects to the 2022 shortage

The Abbott settlement follows the 2022 recall and disruption at the Sturgis, Michigan, factory. The Associated Press reports that the recall, which included Similac products, reduced supplies already strained by pandemic disruptions and stockpiling. Abbott closed the facility in February during an FDA investigation; it had reopened by June. That chronology matters: September’s announcement concerns the civil resolution of older claims, rather than a newly announced plant shutdown or recall. Associated Press report carried by CHCH.

The Abbott settlement bars the company from seeking payment for covered billings from beneficiaries or their parents. It also prevents charging specified settlement and investigation costs to government contracts or Medicaid. Those provisions address who bears the expense of resolving the claims. They do not establish a compensation application for individual families. Agreement, paragraphs 10–12.

The agreement directs the parties to file a joint dismissal after receiving payment. The government’s release depends on receiving its federal share, and specified claims, including criminal liability and personal-injury claims, remain outside that release. Agreement, paragraphs 3, 5 and 13.

Abbott said in its September 14 statement that the government had already closed its criminal investigation into the matter. Company response. The records reviewed do not establish that settlement payment or dismissal has been completed.

Related public-benefits coverage: States and cities challenge immigration rules affecting assistance programs.